{"id":16834,"date":"2013-07-03T01:30:00","date_gmt":"2013-07-02T23:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/aifa-conclude-prima-revisione-prontuario\/"},"modified":"2013-07-03T01:30:00","modified_gmt":"2013-07-02T23:30:00","slug":"aifa-conclude-prima-revisione-prontuario","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/aifa-conclude-prima-revisione-prontuario\/","title":{"rendered":"Aifa concludes first review of the handbook"},"content":{"rendered":"

The Technical-Scientific Commission (Cts) of AIFA has concluded a first revision of the pharmaceutical handbook, i.e. the list of medicines that are reimbursed by the State, according to what is established by the so-called Balduzzi decree: the provision desired by the former Minister of Health in fact provided that , by 30 June, Aifa proceeded with an extraordinary revision of the national formulary, placing the drugs considered therapeutically outdated in band C. <\/p>\n

<\/font><\/span><\/p>\n

And the Cts, according to Pharmakronos, completed the requested work on time. For the official presentation of the new handbook, however, a discussion with stakeholders, such as institutions and representatives of the pharmaceutical supply chain, is expected. <\/p>\n

<\/font><\/span><\/p>\n

Among the novelties of the decree in the pharmaceutical field there was also a provision which provided for the immediate availability of innovative drugs in our country. The mechanism is as follows: all drugs approved with a centralized European procedure or mutual recognition and considered innovative, are automatically included in range C, therefore for payment by the patient. <\/p>\n

<\/font><\/span><\/p>\n

This is unless the manufacturing company submits a request for placement in the ranges of medicines reimbursable by the national health system.<\/p>\n

<\/font><\/span><\/p>\n

BDC \u2013 July 3, 2013 \u2013 PharmaKronos<\/p>\n

<\/span><\/i><\/p>\n

<\/p>\n

 <\/p>\n

<\/span><\/i><\/p>\n

<\/p>\n

 <\/font><\/p>\n

<\/span><\/p>\n

 <\/p>\n

 <\/p>\n

  La Commissione tecnicoscientifica (Cts) dell’Aifa ha concluso una prima revisione del prontuario farmaceutico, cioè l’elenco di medicinali che vengono rimborsati dallo Stato, secondo quanto fissato dal cosiddetto decreto Balduzzi: il provvedimento voluto dall’ex ministro della Salute prevedeva infatti che, entro il 30 giugno, l’Aifa procedesse con una revisione straordinaria del Prontuario nazionale, collocando in fascia …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-16834","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/16834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=16834"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/16834\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=16834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=16834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=16834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}